Galena Biopharma to market anti-vomit oral soluble film to cancer patients

Galena Biopharma ($GALE) believes that its experienced oncology sales team will enable it to effectively market Zuplenz, the only oral soluble film for preventing vomiting following chemotherapy and radiotherapy, which it will soon offer thanks to a licensing agreement struck with MonoSol Rx, the developer of the product's delivery technology. "Adding Zuplenz to our commercial portfolio enhances our offering of supportive care products that are simple to take and provide reliable dosing to improve the quality of life for patients suffering from cancer or recovering from surgery and the associated side-effects," said Galena Biopharma CEO Mark Ahn in a statement. Zuplenz contains ondansetron, which inhibits the neurotransmitter serotonin, thereby reducing nausea and vomiting. Galena says the oral thin strip version of the drug, administered via the top of the tongue, works better than the tablet formulation because it eliminates the burden of swallowing pills during episodes of vomiting, resulting in improved patient compliance. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.